Gabrielle M. Haeusler

Gabrielle M. Haeusler

Auto-generated profile, based on publicly available information

Gabrielle M. Haeusler

Department of Infectious Diseases Unit, Royal Children's Hospital Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TLThomas Lehrnbecher
Thomas Lehrnbecher
PRPaula Robinson
Paula Robinson
BFBrian Fisher
Brian Fisher
SASarah Alexander
Sarah Alexander
RARoland A. Ammann
Roland A. Ammann
LSLillian Sung
Lillian Sung
Purpose: To update a clinical practice guideline (CPG) for the empirical management of fever and neutropenia (FN) in children with cancer and hematopoietic stem-cell transplantation recipients. Methods: The International Pediatric Fever and Neutropenia Guideline Panel is a multidisciplinary and multinational group of experts in pediatric oncology and infectious diseases that includes a patient advocate. For questions of risk stratification and evaluation, we updated systematic reviews of observational studies. For questions of therapy, we conducted a systematic review of randomized trials of any intervention applied for the empirical management of pediatric FN. The Grading of Recommendation Assessment, Development and Evaluation approach was used to make strong or weak recommendations and to classify levels of evidence as high, moderate, low, or very low. Results: Recommendations related to initial presentation, ongoing management, and empirical antifungal therapy of pediatric FN were reviewed; the most substantial changes were related to empirical antifungal therapy. Key differences from our 2012 FN CPG included the listing of a fourth-generation cephalosporin for empirical therapy in high-risk FN, refinement of risk stratification to define patients with high-risk invasive fungal disease (IFD), changes in recommended biomarkers and radiologic investigations for the evaluation of IFD in prolonged FN, and a weak recommendation to withhold empirical antifungal therapy in IFD low-risk patients with prolonged FN. Conclusion: Changes to the updated FN CPG recommendations will likely influence the care of pediatric patients with cancer and those undergoing hematopoietic stem-cell transplantation. Future work should focus on closing research gaps and on identifying ways to facilitate implementation and adaptation.

20 March 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Thomas LehrnbecherThomas Lehrnbecher
Thomas Lehrnbecher
PRPaula D. Robinson
Paula D. Robinson
RARoland A. Ammann
Roland A. Ammann
BFBrian Fisher
Brian Fisher
PPPriya Patel
Priya Patel
LSLillian Sung
Lillian Sung
PURPOSE: To update a clinical practice guideline (CPG) for the empiric management of fever and neutropenia (FN) in pediatric patients with cancer and hematopoietic cell transplantation recipients. METHODS: The International Pediatric Fever and Neutropenia Guideline Panel reconvened to conduct the second update of this CPG. We updated the previous systematic review to identify new randomized controlled trials (RCTs) evaluating any strategy for the management of FN in pediatric patients. Using the Grading of Recommendations Assessment, Development and Evaluation framework, evidence quality was classified as high, moderate, low, or very low. The panel updated recommendations related to initial management, ongoing management, and empiric antifungal therapy. Changes from the 2017 CPG were articulated, and good practice statements were considered. RESULTS: We identified 10 new RCTs in addition to the 69 RCTs identified in previous FN CPGs to inform the 2023 FN CPG. Changes from the 2017 CPG included two conditional recommendations regarding (1) discontinuation of empiric antibacterial therapy in clinically well and afebrile patients with low-risk FN if blood cultures remain negative at 48 hours despite no evidence of marrow recovery and (2) pre-emptive antifungal therapy for invasive fungal disease in high-risk patients not receiving antimold prophylaxis. The panel created a good practice statement to initiate FN CPG-consistent empiric antibacterial therapy as soon as possible in clinically unstable febrile patients. CONCLUSION: The updated FN CPG incorporates important modifications on the basis of recently published trials. Future work should focus on addressing knowledge gaps, improving CPG implementation, and measuring the impact of CPG-consistent care.

1 August 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
BMBrendan J McMullan
Brendan J McMullan
DADavid Andresen
David Andresen
CBChristopher Charles Blyth
Christopher Charles Blyth
MAMinyon L Avent
Minyon L Avent
Asha BowenAsha Bowen
Asha Bowen
PBPenelope A Bryant
Penelope A Bryant

8 December 2014 in Internal Medicine Journal
Verified
Journal Article
Open access
PDF file
SFS. Fleming
S. Fleming
CYC. K. Yannakou
C. K. Yannakou
GHG. M. Haeusler
G. M. Haeusler
JCJ. Clark
J. Clark
AGA. Grigg
A. Grigg
Monica SlavinMonica Slavin
Monica Slavin
There is a strong argument for the use of antifungal prophylaxis in high‐risk patients given the significant mortality associated with invasive fungal disease, the late identification of these infections, and the availability of safe and well‐tolerated prophylactic medications. Clinical decisions about which patients should receive prophylaxis and choice of antifungal agent should be guided by risk stratification, knowledge of local fungal epidemiology, the efficacy and tolerability profile of available agents, and estimates such as number needed to treat and number needed to harm. There have been substantial changes in practice since the 2008 guidelines were published. These include the availability of new medications and/or formulations, and a focus on refining and simplifying patient risk stratification. Used in context, these guidelines aim to assist clinicians in providing optimal preventive care to this vulnerable patient demographic.

1 July 2013 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
GHGabrielle M. Mb Bs Haeusler
Gabrielle M. Mb Bs Haeusler
FMFrancoise Mechinaud
Francoise Mechinaud
ADAndrew J. Mb Bs Daley
Andrew J. Mb Bs Daley
MSMike Mb Bs Starr
Mike Mb Bs Starr
FSFrank Shann
Frank Shann
NCNigel Curtis
Nigel Curtis
Background: Infection with antibiotic-resistant (AR) Gram-negative (GN) bacteria is associated with increased morbidity and mortality. The aim of this study was to determine risk factors and outcomes associated with GN bacteremia with acquired resistance to antibiotics used in the empiric treatment of febrile neutropenia in pediatric oncology patients at our institution. Methods: All episodes of GN bacteremia in oncology patients at the Royal Children’s Hospital Melbourne, from 2003 to 2010 were retrospectively reviewed. Information regarding age, diagnosis, phase of treatment, inpatient status, previous AR GN infection, treatment with inotropes or ventilatory support, admission to intensive care unit, and hospital and intensive care unit length of stay were obtained from electronic records. Results: A total of 280 episodes of GN bacteremia in 210 patients were identified. Of these, 42 episodes in 35 patients were caused by an AR GN organism. Factors independently associated with AR GN bacteremia were high-intensity chemotherapy (odds ratio 3.7, 95% confidence interval: 1.2–11.4), hospital-acquired bacteremia (odds ratio 4.3, 95% confidence interval: 2.0–9.6) and isolation of AR GN bacteria from any site within the preceding 12 months (odds ratio 9.9, 95% confidence interval: 3.8–25.5). Episodes of AR GN bacteremia were associated with longer median hospital length of stay (23.5 days versus 14.0 days; P = 0.0007), longer median intensive care unit length of stay (3.8 days versus 1.6 days; P = 0.02) and a higher rate of invasive ventilation (15% versus 5.2%; P = 0.03). No significant difference in infection-related or all-cause mortality between the 2 groups was identified. Conclusions: In pediatric oncology patients, AR GN bacteremia is associated with an increased rate of adverse outcomes and is more likely in patients who have received high-intensity chemotherapy, have been in hospital beyond 48 hours and who have had previous AR GN infection or colonization.

28 November 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
GHGabrielle M. Haeusler
Gabrielle M. Haeusler
RPRobert S. Phillips
Robert S. Phillips
TLThomas Lehrnbecher
Thomas Lehrnbecher
KTKarin A. Thursky
Karin A. Thursky
LSLillian Sung
Lillian Sung
RARoland A. Ammann
Roland A. Ammann